Skip to main content
Caplight Logo









TETmedical, Inc.

TETmedical, Inc.

Private
Ithaca, New YorkHealthcare & Life Scienceshttps://tetmedical.com

Last Round

Seed Round

Jun 12, 2026

Total Funding Raised

$3.79M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

TETmedical, Inc. operates in Healthcare & Life Sciences and is based in Ithaca, New York. Its latest recorded funding round was a Grant round in December 2023.

TETmedical, Inc. is a diagnostic equipment company that develops an in-vitro diagnostic nanomedicine platform designed for clinical diagnostic use.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

TETmedical, Inc. Comparables

Compare TETmedical, Inc. with similar companies based on industry and business-model similarity.

TETmedical, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Upfront Diagnostics
81%
Galaxy CCRO, Inc.
79%
NanoDx
76%
Book a demo to see all comparables

For institutional investors. Book with your work email.

TETmedical, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundJun 12, 2026
GrantDec 15, 2023
SeedMay 31, 2023
GrantMay 4, 2023
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

TETmedical, Inc. Investors

Notable investors and investment history

TETmedical, Inc. investors
InvestorRounds
Launchpad Venture GroupSeed Round, Seed
NIH RADxGrant
Frontier AngelsSeed Round, Seed
Bantam GroupSeed Round, Seed
Beacon Venture PartnersSeed
eCoast AngelsSeed Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 6, representing 40% of headcount.

  • Jun 12, 2026

    Raised $4M in a seed funding round.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • hiresNov 10, 2026

    On Nov 10th '26, in New Jersey and New York, TETmedical, Inc. announces that Evan Gerber, M.D., is set to serve as a Medical Advisor and advise on clinical strategy, study design, and integrating NSE-FAST into emergency department workflows.

  • hiresNov 10, 2026

    TETmedical, Inc. announces that Hooman Kamel, M.D., M.S., will serve as a Medical Advisor and advise on clinical strategy, study design, and NSE-FAST integration into emergency department workflows in New Jersey and New York on Nov 10th '26.

  • hiresSep 29, 2026

    TETmedical, Inc. appoints Patrick McBrayer to its Board of Directors after he serves as president and CEO of Miach.

  • is_developingSep 29, 2026

    TETmedical, Inc. is developing NSE-FAST to aid in diagnosing acute ischemic stroke by measuring Neuron Specific Enolase activity in plasma, with the product remaining in clinical development ahead of a planned multicenter pivotal study expected to begin in Q4 '26.

  • hiresSep 29, 2026

    TETmedical, Inc. appoints Arjun Ishwar as Chief Commercial Officer on Sep 29th '26 in New Jersey and New York, as he joins its executive leadership team while it advances NSE-FAST(R) toward a multi-center pivotal study and builds commercial infrastructure for launch in the United States and internationally.

Book a demo to see all news

For institutional investors. Book with your work email.

TETmedical, Inc. Filings

Explore SEC and related filing metadata, where available.

TETmedical, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about TETmedical, Inc.'s valuation, stock price, and market status.

Is TETmedical, Inc. a public or private company?

TETmedical, Inc. is a private company.

What is the current stock price of TETmedical, Inc.?

TETmedical, Inc. is a private company, so its shares have no public market price. Caplight tracks TETmedical, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is TETmedical, Inc. worth (valuation)?

Valuation information for TETmedical, Inc. is not publicly available.

Can I buy TETmedical, Inc. stock?

TETmedical, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was TETmedical, Inc.'s last funding round?

TETmedical, Inc.'s most recent funding round was Seed Round on June 12, 2026.

Who are the main investors in TETmedical, Inc.?

Key investors in TETmedical, Inc. include Launchpad Venture Group, NIH RADx, Frontier Angels, Bantam Group, Beacon Venture Partners.

Will TETmedical, Inc. IPO soon?

No public IPO plans have been announced for TETmedical, Inc..

How can I track TETmedical, Inc. secondary market activity?

Caplight tracks bids, offers, and trades in TETmedical, Inc.'s shares on secondary markets.

Firmographic Details

HeadquartersIthaca, New York
Employee Range15
Year Founded2021
Last FundingJun 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?